Abstract
During the transduction of extracellular signals within the cell, the stimulation of specific G protein-coupled receptors (GPCRs) can modulate adenylyl or guanylyl cyclase, phospholipase C activity and ion channels, which regulate second-messengers. These, in turn, trigger several biochemical cascades, including Ca2+ release, activation of protein kinases and gene expression. Significant changes of monoamine GPCR activity may occur in patients suffering from mood disorders and the majority of antidepressants exert part of their effects through GPCR-mediated systems. The main signal transduction pathways activated by metabotropic receptors in the brain and their possible involvement in the pathophysiology of mood disorders will be reviewed herein with a special focus on the horizons opened by this approach in terms of innovative therapeutic strategies.
Keywords: G protein-coupled receptors, central nervous system, adenylyl cyclase, guanylyl cyclase, phospholipase C, mood disorders, antidepressants
Current Medicinal Chemistry
Title: Second Messenger Modulation: A Novel Target of Future Antidepressants?
Volume: 16 Issue: 35
Author(s): D. Marazziti, M. Catena Dell'Osso, G. Consoli and S. Baroni
Affiliation:
Keywords: G protein-coupled receptors, central nervous system, adenylyl cyclase, guanylyl cyclase, phospholipase C, mood disorders, antidepressants
Abstract: During the transduction of extracellular signals within the cell, the stimulation of specific G protein-coupled receptors (GPCRs) can modulate adenylyl or guanylyl cyclase, phospholipase C activity and ion channels, which regulate second-messengers. These, in turn, trigger several biochemical cascades, including Ca2+ release, activation of protein kinases and gene expression. Significant changes of monoamine GPCR activity may occur in patients suffering from mood disorders and the majority of antidepressants exert part of their effects through GPCR-mediated systems. The main signal transduction pathways activated by metabotropic receptors in the brain and their possible involvement in the pathophysiology of mood disorders will be reviewed herein with a special focus on the horizons opened by this approach in terms of innovative therapeutic strategies.
Export Options
About this article
Cite this article as:
Marazziti D., Dell'Osso Catena M., Consoli G. and Baroni S., Second Messenger Modulation: A Novel Target of Future Antidepressants?, Current Medicinal Chemistry 2009; 16 (35) . https://dx.doi.org/10.2174/092986709789878184
DOI https://dx.doi.org/10.2174/092986709789878184 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery
Current Topics in Medicinal Chemistry The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Challenges in Diagnosing Cerebral Lacunar Infarcts
Current Medical Imaging Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews Characterization of a New Positive Allosteric Modulator of AMPA Receptors - PAM-43: Specific Binding of the Ligand and its Ability to Potentiate AMPAR Currents
Current Molecular Pharmacology BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Brain Metabolism of Ethanol and Alcoholism: An Update
Current Drug Metabolism Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Diffusion Tensor Imaging Parameters in Children with Acute Hyperammonemic Encephalopathy due to Urea Cycle Enzyme Defects and Organic Acidemia
Current Medical Imaging Meet Our Editorial Board Member
Current Aging Science Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed β-Sheet Hypothesis
Current Pharmaceutical Design Strain Specificity and Drug Resistance in Anti-Prion Therapy
Current Topics in Medicinal Chemistry Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Current Neuropharmacology Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science